United Therapeutics Corporation (UTHR) Director Christopher Causey Sells 580 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $134.72, for a total value of $78,137.60. Following the completion of the transaction, the director now directly owns 1,555 shares of the company’s stock, valued at $209,489.60. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Christopher Causey also recently made the following trade(s):

  • On Monday, November 6th, Christopher Causey sold 580 shares of United Therapeutics stock. The stock was sold at an average price of $122.00, for a total value of $70,760.00.
  • On Thursday, October 5th, Christopher Causey sold 580 shares of United Therapeutics stock. The stock was sold at an average price of $122.00, for a total value of $70,760.00.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up $2.83 during trading on Thursday, reaching $137.07. The company had a trading volume of 440,088 shares, compared to its average volume of 555,601. United Therapeutics Corporation has a twelve month low of $112.01 and a twelve month high of $169.89. The company has a market cap of $5,797.63, a price-to-earnings ratio of 11.83 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The business had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same period in the previous year, the company posted $4.23 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. research analysts forecast that United Therapeutics Corporation will post 12.45 EPS for the current year.

Several research analysts have recently weighed in on the company. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. TheStreet lowered United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Oppenheimer reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. ValuEngine raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. Finally, Cowen reaffirmed a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a research report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $136.10.

A number of institutional investors have recently modified their holdings of UTHR. HPM Partners LLC increased its holdings in United Therapeutics by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares in the last quarter. First Allied Advisory Services Inc. increased its holdings in United Therapeutics by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after purchasing an additional 19 shares in the last quarter. Synovus Financial Corp increased its holdings in United Therapeutics by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after purchasing an additional 69 shares in the last quarter. Ifrah Financial Services Inc. increased its holdings in United Therapeutics by 1.7% during the 2nd quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 76 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in United Therapeutics by 2.3% during the 2nd quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock worth $496,000 after purchasing an additional 86 shares in the last quarter. 99.94% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/07/united-therapeutics-corporation-uthr-director-christopher-causey-sells-580-shares.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit